Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol - Zynerba Pharmaceuticals

Next Previous
Drug Profile

Cannabidiol - Zynerba Pharmaceuticals

Alternative Names: Cannabidiol gel patch; Cannabidiol transdermal gel; CBD; CBD gel patch; CBD transdermal gel; Synthetic CBD; Topical cannabidiol gel; Topical CBD gel; Transdermal CBD gel; Zygel; ZYN-002

Latest Information Update: 13 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zynerba Pharmaceuticals
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
  • Mechanism of Action 5-HT1 serotonin receptor modulators; Antioxidants; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome; DiGeorge syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Fragile X syndrome
  • Phase II Autism spectrum disorder; DiGeorge syndrome; Epilepsy
  • No development reported Alcoholism; Rheumatoid arthritis; Substance-related disorders
  • Discontinued Osteoarthritis

Most Recent Events

  • 05 Aug 2025 Harmony Biosciences plans a phase III registrational trial in DiGeorge Syndrome in fourth quarter of 2025
  • 06 Jun 2025 Harmony Biosciences Management initiates enrolment in a phase I drug-drug trial in Australia (NCT06930872)
  • 06 May 2025 Harmony Biosciences completes enrolment in its phase-III RECONNECT clinical trials in Fragile X syndrome (In adolescents, In children, In adults) in Australia, New Zealand, United Kingdom, Ireland and USA (Transdermal) (ACTRN12621000874819), (NCT04977986)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top